NAICS Code 621111-23 - Prostate Screening

Marketing Level - NAICS 8-Digit

Business Lists and Databases Available for Marketing and Research

Total Verified Companies: Inquire
Contact Emails: 1
Company Websites: Inquire
Phone Numbers: Inquire
Business Addresses: Inquire
Companies with Email: Inquire
Get Business List
NAICS CODE 621111-23
Reach new customers, connect with decision makers, and grow your business.
Pricing from $0.05 to $0.25 per lead
Ideal for: Direct Mailing Email Campaigns Calling Market Research ‐ Free Sample & Report, Custom Lists, and Expert Support — All Included
Looking for more companies? See NAICS 621111 - Offices of Physicians (except Mental Health Specialists) - 892,121 companies, 2,360,298 emails.

NAICS Code 621111-23 Description (8-Digit)

Prostate screening is a medical industry that focuses on the early detection and diagnosis of prostate cancer in men. This industry involves a range of medical procedures and tests that are designed to identify the presence of cancerous cells in the prostate gland. Prostate screening is an important aspect of men's health, as early detection of prostate cancer can significantly improve the chances of successful treatment and recovery.

Parent Code - Official US Census

Official 6‑digit NAICS codes serve as the parent classification used for government registrations and documentation. The marketing-level 8‑digit codes act as child extensions of these official classifications, providing refined segmentation for more precise targeting and detailed niche insights. Related industries are listed under the parent code, offering a broader context of the industry environment. For further details on the official classification for this industry, please visit the U.S. Census Bureau NAICS Code 621111 page

Tools

Tools commonly used in the Prostate Screening industry for day-to-day tasks and operations.

  • Digital rectal exam (DRE)
  • Prostate-specific antigen (PSA) blood test
  • Transrectal ultrasound (TRUS)
  • Magnetic resonance imaging (MRI)
  • Biopsy needle
  • Prostate biopsy gun
  • Prostate biopsy forceps
  • Prostate biopsy needle guide
  • Prostate biopsy needle
  • Prostate biopsy specimen container

Industry Examples of Prostate Screening

Common products and services typical of NAICS Code 621111-23, illustrating the main business activities and contributions to the market.

  • Prostate cancer screening
  • Prostate cancer diagnosis
  • Prostate biopsy
  • Prostate-specific antigen (PSA) testing
  • Digital rectal exam (DRE)
  • Transrectal ultrasound (TRUS)
  • Magnetic resonance imaging (MRI)
  • Prostate cancer treatment planning
  • Prostate cancer surveillance
  • Prostate cancer research

History

A concise historical narrative of NAICS Code 621111-23 covering global milestones and recent developments within the United States.

  • Prostate screening has been a topic of interest for many years, with the first screening test being developed in the 1980s. The prostate-specific antigen (PSA) test was introduced in the late 1980s and became widely used in the 1990s. In 2012, the US Preventive Services Task Force recommended against routine PSA screening for prostate cancer, citing concerns about overdiagnosis and overtreatment. However, in recent years, there has been a renewed interest in prostate screening, with new tests and technologies being developed to improve accuracy and reduce the risk of unnecessary treatment. For example, the Prostate Health Index (PHI) test, which combines PSA with other biomarkers, has been shown to be more accurate than PSA alone. Additionally, MRI-guided biopsy has been shown to be more accurate than traditional biopsy methods, reducing the need for repeat biopsies and improving patient outcomes.